Karyopharm Therapeutics (NASDAQ:KPTI) Announces Quarterly Earnings Results


Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) announced its earnings results on Sunday. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.06), MarketWatch Earnings reports. Karyopharm Therapeutics had a negative return on equity of 187.66% and a negative net margin of 221.23%.

Shares of KPTI stock traded down $0.96 on Tuesday, reaching $8.48. The company had a trading volume of 3,723,849 shares, compared to its average volume of 2,442,094. The business’s 50-day moving average is $10.41 and its 200 day moving average is $14.01. Karyopharm Therapeutics has a one year low of $8.43 and a one year high of $21.82. The company has a quick ratio of 5.39, a current ratio of 5.42 and a debt-to-equity ratio of 1.38. The stock has a market capitalization of $636.52 million, a PE ratio of -2.94 and a beta of 0.93.

KPTI has been the topic of a number of analyst reports. SVB Leerink reduced their price target on Karyopharm Therapeutics from $22.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday. Royal Bank of Canada reduced their target price on Karyopharm Therapeutics from $24.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday. Zacks Investment Research downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, February 18th. Robert W. Baird reduced their price objective on shares of Karyopharm Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Tuesday. Finally, Barclays decreased their target price on shares of Karyopharm Therapeutics from $26.00 to $22.00 and set an “overweight” rating on the stock in a report on Friday, February 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Karyopharm Therapeutics currently has a consensus rating of “Buy” and an average target price of $27.00.

In related news, insider Sharon Shacham sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, March 18th. The shares were sold at an average price of $12.39, for a total transaction of $49,560.00. Following the completion of the transaction, the insider now directly owns 920,152 shares in the company, valued at approximately $11,400,683.28. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 14,681 shares of company stock worth $207,959 over the last ninety days. 13.26% of the stock is currently owned by insiders.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1.

Recommended Story: ESG Score

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.